Cargando…
Severe drug-associated colitis with Crohn’s features in setting of ixekizumab therapy for chronic plaque psoriasis
BACKGROUND: Ixekizumab is monoclonal antibody targeted against interleukin-17 (IL-17) and has been approved for use in chronic plaque psoriasis. Despite its efficacy in treating psoriasis, concerns have been raised regarding Ixekizumab’s potential to induce and exacerbate inflammatory bowel disease...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487480/ https://www.ncbi.nlm.nih.gov/pubmed/34600483 http://dx.doi.org/10.1186/s12876-021-01936-w |